Hostname: page-component-745bb68f8f-l4dxg Total loading time: 0 Render date: 2025-01-11T22:40:40.449Z Has data issue: false hasContentIssue false
  • English
  • Français

Informed Consent Should Be a Required Element for Newborn Screening, Even for Disorders with High Benefit-Risk Ratios

Published online by Cambridge University Press:  01 January 2021

Norman Fost
Get access Rights & Permissions [Opens in a new window]

Abstract

Over-enthusiastic newborn screening has often caused substantial harm and has been imposed on the public without adequate information on benefits and risks and without parental consent. This problem will become worse when genomic screening is implemented. For the past 40 years, there has been broad agreement about the criteria for ethically responsible screening, but the criteria have been systematically ignored by policy makers and practitioners. Claims of high benefit and low risk are common, but they require precise definition and documentation, which has often not occurred, undermining claims that involuntary testing is justified. Even when the benefits and risks are well established, it does not automatically follow that involuntary testing is justified, a position supported by the widespread tolerance for parental refusal of immunizations and newborn screening.

Type
Symposium Articles
Information
Journal of Law, Medicine & Ethics , Volume 44 , Issue 2: Ethical and Legal Issues in Pediatrics , Summer 2016 , pp. 241 - 255
Copyright
Copyright © American Society of Law, Medicine and Ethics 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Wasserstein, M., “Screening of Newborns for Disorders with High Benefit-Risk Ratios,” Journal of Law, Medicine & Ethics 42, no. 2 (2016).Google Scholar
Santayana, G., “Reason in Common Sense,” volume 1 of The Life of Reason (1905): at 284.Google Scholar
Olmstead v. United States, 277 U.S. 438 (1928),Google Scholar
Faden, R. and Beauchamp, T., A History and Theory of Informed Consent (Oxford University Press: New York, 1986).Google Scholar
FDA Review, “The Drug Development and Approval Process,” available at <http://www.fdareview.org/approval_process.shtml> (last visited April 25, 2016).+(last+visited+April+25,+2016).>Google Scholar
Protection of Human Subjects, 45CFR46.116(c)Google Scholar
Botkin, J. R., Lewis, M. H., Watson, M. S., Swoboda, K. J., Anderson, R., Berry, S. A., Bonhomme, N., Brosco, J. P., Comeau, A. M., Goldenberg, A., Goldman, E., Therrell, B., Levy-Fisch, J., Tarini, B., and Wilfond, B., “Bioethics and Legal Work Group of the Newborn Screening Translational Research Network: Parental Permission for Pilot Newborn Screening Research: Guidelines from the NBSTRN,” Pediatrics 133, no. 2 (2014): e410-7; J. R. Botkin, “Research for Newborn Screening: Developing a National Framework,” Pediatrics 116 (2005): 862-871.Google Scholar
Alexander, D. and van Dyck, P. C., “A Vision of the Future of Newborn Screening,” Pediatrics 117, no. 5 (2006): S350-354.CrossRefGoogle Scholar
Waisman, H. A., “Role of Phenylalanine Excess in Experimental Phenylketonuria,” Research Publications - Association for Research in Nervous and Mental Disease 40 (1962): 300-310.Google Scholar
Guthrie, R. and Susi, A., “A Simple Phenylalanine Method for Detecting Phenylketonuria in Large Populations of Newborn Infants,” Pediatrics 32, no. 9 (1963): 338-343.Google Scholar
Paul, D., “Appendix 5. The History of Newborn Phenylketonuria Screening in the U.S.,” in Promoting Safe and Effective Genetic Testing in the United States: Final Report of the Task Force on Genetic Testing, Holtzman, N. A. and Watson, M. S., eds., September 1997, available at <http://biotech.law.lsu.edu/research/fed/tfgt/appendix5.htm> (last visited April 25, 2016).+(last+visited+April+25,+2016).>Google Scholar
Brosco, J. P., Sanders, L. M., Seider, M. I., and Dunn, A. C., “Adverse Medical Outcomes of Early Newborn Screening Programs for Phenylketonuria,” Pediatrics 122 (2008): 192–197.Google Scholar
Brosco, P. D. and Paul, D., The PKU Paradox: A Short History of a Genetic Disease (electronic edition) (Baltimore: Johns Hopkins Press, 2014).Google Scholar
Id.Google Scholar
Id., at 121.Google Scholar
Id., at 129.Google Scholar
Salehpour, S. and Babaie, D., “Mismanagement of Phenylketonuria: an Underlying Cause of Kwashiorkor,” Iranian Journal of Child Neurology 2, no. 4 (2008): 59-61.Google Scholar
American Academy of Pediatrics Committee on Genetics, “Maternal Phenylketonuria,” Pediatrics 122 (2008): 445–449.Google Scholar
Hanley, W. B., Clarke, J. T. R., and Schoonheyt, W., “Maternal Phenylketonuria: A Review,” Clinical Biochemistry 20 (1987): 149-156.CrossRefGoogle Scholar
Maillot, F., Lilburn, M., Baudin, J., Morley, D. W., and Lee, P., “Factors Influencing outcomes in the Offspring of Mothers with Phenylketonuria during Pregnancy: The Importance of Variation in Maternal Blood Phenylalanine,” American Journal of Clinical Nutrition 88, no. 3 (2008): 700-705.CrossRefGoogle Scholar
See Brosco and Paul, supra note 13, at 117.Google Scholar
Id., at 118.Google Scholar
Id., at 119.Google Scholar
Simopoulos, A. P. and Committee for the Study of Inborn Errors of Metabolism, Division of Medical Sciences, Assembly of Life Sciences, National Research Council, Genetic Screening: Programs, Principles, and Research (Washington, D.C.: National Academy of Sciences, 1975). See also, A. P. Simopoulos and the Committee for the Study of Inborn Errors of Metabolism (SIEM), “Genetic Screening: Programs, Principles, and Research--Thirty Years Later. Reviewing the Recommendations of the Committee for the Study of Inborn Errors of Metabolism (SIEM),” Public Health Genomics 12, no. 2 (2009): 105-111.Google Scholar
Wilson, J. M. and Jungner, Y. G.. “Principles and Practice of Mass Screening for Disease,” Boletín de la Oficina Sanitaria Panamericana 65, no. 4 (1968): 281-393.Google Scholar
Andrews, L. B., Fullarton, J. E., Holtzman, N. A., and Motulsky, A. G., eds., Committee on Assessing Genetic Risks, Division of Health Sciences Policy, Institute of Medicine, Assessing Genetic Risks: Implications for Health and Social Policy (Washington, D.C.: National Academy Press, 1994).Google Scholar
See Simopoulos, supra note 23 and id. (Andrews).Google Scholar
President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, Screening and Counseling for Genetic Conditions: The Ethical, Social and Legal Implications of Genetic Screening, Counseling and Education Programs (Washington, D.C.: US Government Printing Office, 1983).Google Scholar
See Ross, infra note 40.Google Scholar
Lappe, M., Gustafson, J., and Roblin, R., “Ethical and Social Issues in Screening for Genetic Disease,” New England Journal of Medicine 286 (1979): 1129-1132.CrossRefGoogle Scholar
See Ross, infra.Google Scholar
Andermann, A., Blancquaert, I., Beauchamp, S., and Dery, V., “Revisiting Wilson and Jungner in the Genomic Age: A Review of Screening Criteria over the Past 40 years,” Bulletin of the World Health Organization 86, no. 4 (2008): 317-319.Google Scholar
See Botkin et al., supra note 7.Google Scholar
See supra note 6.Google Scholar
“American Academy of Pediatrics Statement of Compulsory Testing of Newborns for Metabolic Disorders,” Pediatrics 39, no. 4 (1967): 84-85.Google Scholar
Grob, R., Testing Baby: The Transformation of Newborn Screening, Parenting and Policymaking (New Brunswick: Rutgers University Press, 1966).Google Scholar
Firth, R., “Ethical Absolutism and the Ideal Observer,” Philosophy and Phenomenological Research 12 (1952): 317.CrossRefGoogle Scholar
Holtzman, N. A., Proceed with Caution: Predicting Genetic Risks in the Recombinant DNA Era (Baltimore: Johns Hopkins Press, 1989); Botkin, J. R., Clayton, E. W., Fost, N. C., Burke, W., Murray, T. H., Baily, M., Wilfond, B., Berg, A., and Ross, L. R., “Newborn Screening Technology: Proceed with Caution,” Pediatrics 117, no. 5 (2006): 1793-1799.Google Scholar
Id. (Holtzman).Google Scholar
Ross, L. F., Saal, H. M., David, K. L., Anderson, R. R., and the American Academy of Pediatrics and American College of Medical Genetics, “Technical Report: Ethical and Policy Issues in Genetic Testing and Screening of Children,” Genetics in Medicine 15, no. 3 (2013): 234-245; American Academy of Pediatrics Committee on Bioethics, Committee on Genetics, and the American College of Medical Genetics, and Genomics Social, Ethical and Legal Issues Committee, “Ethical and Policy Issues in Genetic Testing and Screening of Children,” Pediatrics 131, no. 3 (2013): 620-622.CrossRefGoogle Scholar
Usher, R., “Reduction in Mortality from Respiratory Distress Syndrome Prematurity with Early Administration of Intravenous Glucose and Sodium Bicarbonate,” Pediatrics 32 (1963): 966-975.Google Scholar
Hein, H., “The Use of Sodium Bicarbonate in Neonatal Resuscitation: Help or Harm?” Pediatrics 91 (1993): 496-497.Google Scholar
Odell, G. B., “Therapeutic Misadventures in Neonatal Care,” in Gluck, L., ed., Modern Perinatal Medicine (Chicago: Yearbook Medical Publishers, 1956): at 323-327.Google Scholar
Ostrea, E. M. and Odell, G. B., “The Influence of Bicarbonate Administration on Blood pH in a ‘Closed System,’: Clinical Implications,” Journal of Pediatrics 80 (1972): 671-680; G. B. Odell, “Therapeutic Misadventures in Neonatal Care,” in L. Gluck, ed., Modern Perinatal Medicine (Chicago: Yearbook Medical Publishers, 1956): at 323-327.CrossRefGoogle Scholar
Finberg, L., “The Relationship of Intravenous Infusions and Intracranial Hemorrhage: A Commentary,” Journal of Pediatrics 91 (1977): 777-778.Google Scholar
Simmons, M. A., Adcock, E. W. 3rd, Bard, H., and Battaglia, F. C., “Hypernatremia and Intracranial Hemorrhage in Neonates,” New England Journal of Medicine 291, no. 1 (1974): 6-10.CrossRefGoogle Scholar
Aschner, J. L. and Poland, R. L., “Sodium Bicarbonate: Basically Useless Therapy,” Pediatrics 122 (2008): 831-835.CrossRefGoogle Scholar
Watchko, J. and Oski, F., “Biliruibin 20 mg/dl = vigintophobia,” Pediatrics 71 (1983): 660-663.Google Scholar
Newman, T., Liljestrand, P., Jeremy, R. et al., “Outcomes among Newborns with Total Serum Bilirubin Levels of 25 mg per Deciliter or More,” New England Journal of Medicine 354, no. 18 (2006): 1889-1900.CrossRefGoogle Scholar
Newman, T. B., Liljestrand, P., and Escobar, G., “Infants with Bilirubin of 30 mg/dl or More in a Large Managed Care Organization,” Pediatrics 111, no. 6 (2003): 1303-1311.Google Scholar
Newman, T. B. and Maisels, M. J., “Does Hyperbilirubinemia Damage the Brain of Healthy Full-Term Infants?” Clinics in Perinatology 17, no. 2 (1990): 331-358.CrossRefGoogle Scholar
Jablonski, W. J., “Risks Associated with Exchange Transfusion,” New England Journal of Medicine 266, no. 4 (1962): 155-160.CrossRefGoogle Scholar
Trolle, D., “Discussion on the Advisability of Performing Exchange Transfusion in Neonatal Jaundice of Unknown Etiology,” Acta Paediatrica 58 (1961): 392-398.CrossRefGoogle Scholar
Silverman, W. A., “A Cautionary Tale About Supplemental Oxygen: The Albatross of Neonatal Medicine,” Pediatrics 113 (2004): 394-396.CrossRefGoogle Scholar
Patz, A., Hoeck, L. E., and de la Cruz, E., “Studies on the Effect of High Oxygen Administration in Retrolental Fibroplasia. 1. Nursery Observations,” American Journal of Ophthalmology 35 (1952): 1248-1253.CrossRefGoogle Scholar
Tin, W. and Gupta, S., “Optimum Oxygen Therapy in Preterm Babies,” Archives of Disease in Child: Fetal Neonatal Ed. 92, no. 2 (2007): F143-F147.CrossRefGoogle Scholar
Watson, vM. S., Lloyd-Puryear, M. A., Mann, M. Y., Rinaldo, P., and Rodney Howell, R., eds., Genetics in Medicine 8, Suppl. (2006): 12S-252S, available at <https://www.acmg.net/resources/policies/NBS/NBS_Main_Report_00.pdf> (last visited April 26, 2016).+(last+visited+April+26,+2016).>Google Scholar
See supra note 1.Google Scholar
Moyer, V. A., Calonge, N., Teutsch, S. M., and Botkin, J. R., on Behalf of the United States Preventive Services Task Force, “Expanding Newborn Screening: Process, Policy, and Priorities,” Hastings Center Report 38, no. 3 (2008): 32-39. See especially Note 16. This report is also available at <http://www.uspreventiveservicestaskforce.org/uspstf08/methods/newbscr.htm#copyright> (last visited April 26, 2016).CrossRefGoogle Scholar
See Botkin, supra note 38; Natowicz, N., “Newborn Screening–Setting Evidence Based Policy for Protection,” New England Journal of Medicine 353 (2005): 867-870.CrossRefGoogle Scholar
Howell, R. R., “We Need Expanded Newborn Screening,” Pediatrics 117, no. 5 (2006): 1800-1805.Google Scholar
Pandor, A., Eastham, J., Beverley, C., Chilcott, J., and Maisley, S., “Clinical Effectiveness and Cost-Effectiveness of Neonatal Screening for Inborn Errors of Metabolism Using Tandem Mass Spectrometry: A Systematic Review,” Health Technology Assessment 8, no. 12 (2004): 1-309.Google Scholar
MBADD is the acronym for 2-methylbutyryl-CoA dehydrogenase deficiency.Google Scholar
Van Calcar, S. C., Gleason, L. A., Hoffman, G., Rhead, V. V., Vockley, G., Wolff, J. A., and Durkin, M. S., “2-methylbutyryl-CoA Dehydrogenase Deficiency in Hmong Infants Identified by Expanded Newborn Screen,” Wisconsin Medical Journal 106, no. 1 (2007): 12-15.Google Scholar
Kokotos, F., “The Vulnerable Child Syndrome,” Pediatrics in Review 30, no. 5 (2009): 193-194.CrossRefGoogle Scholar
Fost, N. and Kaback, N. M., “Why Do Sickle Screening in Children?” Pediatrics 51, no. 4 (1973): 742-745.Google Scholar
Stamatoyannopoulus, G., “Problems of Screening and Counseling in the Hemoglobinopathies,” in Motulsky, A. G. and Lenz, W., eds., Birth Defects: Proceedings of the 4th International Conference, Vienna, Austria, September 28, 1973.Google Scholar
Severo, R., “Blacks Only Need Apply,” The Nation, September 20, 1980, at 243-245.Google Scholar
NIH Program Explores the Use of Genomic Sequencing in Newborn Healthcare, National Institutes of Health, September 4, 2013, available at <http://www.nih.gov/news/health/sep2013/nhgri-04.htm> (last visited April 27, 2016).+(last+visited+April+27,+2016).>Google Scholar
Alexander, D. and Hanson, J. W., “NICHD Research Initiative in Newborn Screening,” Mental Retardation and Developmental Disabilities Research Reviews 12, no. 4 (2006): 301-304.CrossRefGoogle Scholar
Wisconsin Statutes 253.13(3). Tests for congenital disorders: Exceptions.Google Scholar
Kraszewski, J., Burke, T., and Rosenbaum, S., “Legal Issues in Newborn Screening: Implications for Public Health Practice and Policy,” Public Health Reports 121, no. 1 (2006): 92-94.CrossRefGoogle Scholar
Committee on Bioethics, Committee on Genetics, and the American College of Medical Genetics and Genomics Social, Ethical, and Legal Issues Committee, “Ethical and Policy Issues in Genetic Testing and Screening of Children,” Pediatrics 131, no. 3 (2013): 620-622.CrossRefGoogle Scholar
See Botkin, supra note 7.Google Scholar
See Botkin, Lewis et al., supra note 7.Google Scholar
Perrin, J. M., Knapp, A. A., Browning, M. F., Comeau, A. M., Green, N. S., Lipstein, E. A., Metterville, D. R., Prosser, L., Queally, D., and Kemper, A. R., “An Evidence Development Process for Newborn Screening,” Genetics in Medicine 12, no. 3 (2010): 131-134CrossRefGoogle Scholar
Letter from Sylvia Burwell to Joseph Bocchini Jr., available at <http://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders/recommendations/correspondence/secretaryfinalresponse.pdf> (last visited May 23, 2016).+(last+visited+May+23,+2016).>Google Scholar
Golden-grant, K., IIMerritt, J. L., and Scott, C. R., “Ethical Considerations of Population Screening for Late-Onset Genetic Disease,” Clinical Genetics 88 (2015): at 589-592.Google Scholar
See Botkin, Lewis et al., supra note 7; Green, M. J., Biesecker, B. B., McInerney, A. M., Mauger, D. T. and Fost, N., “An Interactive Computer Program Can Effectively Educate Patients about Genetic Testing for Breast Cancer Susceptibility,” American Journal of Medical Genetics 103 (2001): 16-23; Mahnke, A. N., Plasek, J. M., Hoffman, D. G., Partridge, N. S., Foth, W. S., Waudby, C. J., Rasmussen, L. V., MacManus, V. D., and McCarty, C. A., “A Rural Community's Involvement in the Design and Usability testing of a Computer-Based Informed Consent Process for the Personalized Medicine Research Project,” American Journal of Medical Genetics 164A, no. 1 (2014): 129-140.CrossRefGoogle Scholar